Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Compounding Pharmacy Oversight Changes Signed

By Pharmaceutical Processing | July 11, 2014

BOSTON (AP) — Two years after a deadly nationwide meningitis outbreak linked to a compounding pharmacy in Massachusetts, Gov. Deval Patrick on Thursday signed a law he said would address a “gray area” between state and federal oversight of the pharmacies.

The measure includes new licensing and labeling requirements and steps up fines for violations of state rules.

It also reorganizes the board that oversees pharmacies and requires the board’s inspectors to be trained in sterile and non-sterile compounding practices.

A tainted steroid produced by the now-closed New England Compounding Center in Framingham was blamed for the fungal meningitis outbreak that caused 64 deaths and hundreds of illnesses in 20 states.

“I think this puts us ahead of other states,” Patrick said after a Statehouse bill-signing ceremony. “The gray area that I and so many other people talked about is an area of considerable ambiguity about where state authority leaves off and federal authority begins.”

While the U.S. Food and Drug Administration regulates large drug manufacturers, compounding pharmacies that mix and ship medications in bulk — like the one that operated in Framingham — often fell under less stringent state oversight.

The law would create four new categories of specialty licenses, including one for out-of-state pharmacies doing business in Massachusetts.

Pharmacies could be fined up to $25,000 per violation, with an additional $1,000 for each day a violation continues after it was supposed to be corrected.

While the state stepped up emergency inspections of compounding pharmacies after the 2012 outbreak, legislators said they worked at a more deliberate pace to craft a permanent law regulating the facilities.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE